Average duration of indomethacin use was 22 months and 24 months for SBSE. Once at therapeutic doses, indomethacin took on average 3.0 days to become effective, whereas SBSE took 13 days. Migraine Disability Assessment Scores were 52 (pre-treatment), 20 (while on indomethacin) and 16 while on SBSE. Average pain scores and headache days per month were 7.5/30, 3.3/13 and 3.6/16 respectively. The overall perceived benefit score (0-10) of indomethacin was 7.7 and 7.8 for SBSE. Subjects reported side effects with indomethacin 72% of the time and 15% of the time with SBSE. Side effects with indomethacin versus SBSE were nausea (38%/8%), dyspepsia (29%/4%), fatigue (25%/15%), insomnia (25%/23%), poor concentration (21%/8%), “spacey” feeling (21%/4%), poor memory (17%/8%), bloating (17%/15%) and dizziness (8%/0%). SBSE was void of adverse events whereas indomethacin was associated with easy bleeding/bruising (5%), anemia (5%), anaphylaxis (5%), gastric ulceration (5%), intestinal ulceration (5%), lower gastrointestinal bleeding (5%), hemorrhoidal bleeding (8%) and impaired renal function (8%).